Mediar Therapeutics closed an oversubscribed $76 million Series B co‑led by ICG Life Sciences and Amplitude Ventures to accelerate clinical development of multiple anti‑fibrotic antibodies. The financing brings Mediar’s total capital raised to about $175 million and funds Phase IIa studies and additional programs targeting skin, lung and kidney fibrosis. Mediar’s lead asset, MTX‑474, targets EphrinB2 to block myofibroblast activation and is in a Phase IIa study in systemic sclerosis; MTX‑463, a WISP1‑directed antibody, is in Phase IIa for idiopathic pulmonary fibrosis under a collaboration with Eli Lilly. CEO Rahul Ballal said the round allows the company to run rigorous, placebo‑controlled studies designed to deliver powered readouts on validated endpoints such as modified Rodnan skin score. Investors noted the scarcity of robust anti‑fibrotic modalities and the opportunity for upstream myofibroblast targeting to alter disease trajectories in high‑unmet‑need indications.